Common Safety Follow-up Trial of Tecemotide (L-BLP25): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Common Safety Follow-up Trial of Tecemotide (L-BLP25) (NCT01423760), a non-randomized na study. The primary outcome is Number of Subjects With Adverse Events (AEs), Serious AEs, AEs Leading to Discontinuation and AEs Leading to Death.

2. Clinical Question

The central statistical question is descriptive: what adverse events were recorded among participants treated with tecemotide during follow-up? The primary endpoint is a set of counts of participants, rather than a comparison of treatment effects between randomized groups. Its categories cover adverse events generally, serious adverse events, events leading to discontinuation, and events leading to death. The safety population is restricted to participants who received tecemotide.

The record describes a common follow-up study for participants transferring from earlier trials after those trials met their objectives. Some continued tecemotide, while others were observed without receiving it in this trial. Because treatment status was not randomized in the follow-up study and the groups entered under different circumstances, differences between them would not isolate a treatment effect. The registry record does not report an adjusted comparative estimate or an efficacy conclusion. Overall survival is listed as a secondary outcome, but its result is not reported in the registry record.

3. Trial Design

This was an open-label, nonrandomized, parallel-model follow-up trial of tecemotide (L-BLP25). The registry lists the phase as NA and enrollment as 27. The listed conditions are non-small cell lung cancer and multiple myeloma. The sponsor is Merck KGaA, Darmstadt, Germany. The recorded start was 2012-01, the primary completion was 2015-07, and the trial status is terminated.

Participants had taken part in earlier sponsored tecemotide trials. They transferred to this follow-up once the feeder-trial objectives were met. Those who had received tecemotide in a feeder trial continued it in the follow-up and had safety assessments. Those who had not received it, or had discontinued treatment, were observed for progressive disease and survival but did not receive tecemotide in this study. Observation for progressive disease and survival was scheduled in 6-month intervals.

Open-label means treatment assignment was not masked. Nonrandomized means assignment to the study’s treatment or observation circumstances was not allocated by random assignment. The record therefore does not describe a randomized efficacy comparison. Its parallel model and intervention listings include tecemotide and no intervention, but the groups arose from prior treatment history and continuation decisions, rather than from randomized allocation within this study.

The primary outcome concerns numbers of participants with adverse events, serious adverse events, events leading to discontinuation, and events leading to death. Safety analyses included only participants treated with tecemotide. Overall survival is listed as a secondary outcome. The reason for termination, the detailed rationale for enrollment, and any sample-size justification are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Subjects who participated in the tecemotide (L-BLP25) clinical trials (EMR 63325-005, EMR 63325-006, and EMR 63325-008 served as feeder studies) were considered in this follow-up study after the protocol specific inclusion and exclusion criteria to continue their maintenance treatment. A total of 27 subjects were enrolled in this follow-up study.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Only subjects treated with tecemotide were included in the safety analysis set.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Screening analysis set included all the subjects included in the trial.

6. Primary Endpoint

The registry lists the primary outcome as Number of Subjects With Adverse Events (AEs), Serious AEs, AEs Leading to Discontinuation and AEs Leading to Death, measured over Screening up to 42 days after last dose of study treatment with tecemotide (L-BLP25), assessed up to 3.6 years.

The primary endpoint counts participants with adverse events, serious adverse events, adverse events leading to treatment discontinuation, and adverse events leading to death. An adverse event is defined in the registry as a new untoward medical occurrence or worsening of a pre-existing condition, without regard to whether it might have been caused by treatment. A serious adverse event is defined by outcomes including death, a life-threatening event, persistent or significant disability or incapacity, initial or prolonged inpatient hospitalization, and congenital anomaly or birth defect.

Counting participants provides a direct description of how many people in the safety population experienced the listed event categories. It can help characterize the observed safety experience during the specified observation period. These counts do not, by themselves, establish that tecemotide caused an event. The definition explicitly does not require a causal relationship, and the study was open-label and nonrandomized.

The endpoint timeframe runs from screening up to 42 days after the last dose of study treatment with tecemotide, assessed up to 3.6 years. Only participants treated with tecemotide were included in the safety analysis set. The registry record does not report a single aggregate count for every primary endpoint category in the endpoint description; it does report condition-specific adverse-event counts, including serious adverse-event counts. Results for events leading to discontinuation and events leading to death are not reported in the registry record. Overall survival is a secondary outcome, not the primary safety endpoint, and its results are not reported.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The most appropriate statistical reading begins with the endpoint’s scale. The primary outcome is a count of participants with specified adverse-event categories. A participant count is a descriptive summary: it records how many people met an event definition during the stated observation period. It is not the same as a count of all event episodes, because a participant may experience more than one event. The registry’s endpoint wording asks for numbers of subjects, and the posted figures should be interpreted as participant counts.

What can counts tell a reader?

Counts indicate the observed burden in the participants included in the relevant safety group. The record lists serious adverse-event counts separately for non-small cell lung cancer and multiple myeloma, as well as counts for other adverse events. Counts are useful when the question is how many participants had a recorded event. They are less informative about comparative risk unless the groups are comparable and their observation periods are understood. A denominator gives context, but a count and denominator still do not capture differences in follow-up duration or treatment exposure.

In general, a proportion is a count divided by the number of people eligible for that count. The registry’s group entries include participants at risk and participants affected, but no newly calculated proportions are needed to interpret the record. The reported serious adverse-event term percentages are presented as such in the registry; their denominator and derivation are not reported in the registry record. A percentage is only interpretable when its underlying population and event-counting method are clear.

Why does the design limit comparison?

Random allocation is used in general to make treatment groups more comparable with respect to measured and unmeasured characteristics. This study was nonrandomized. Participants continued treatment or entered observation based on their prior trial treatment and discontinuation history. These histories can be associated with prognosis, prior exposure, health status, and duration of follow-up. Therefore, comparing observed counts between the tecemotide and observation circumstances would be vulnerable to confounding and selection effects. The record explicitly cautions that the arms are not a like-for-like control comparison.

Open-label status means participants and study personnel were not masked to treatment. In general, awareness of treatment can affect reporting, assessment, or clinical management, even when an outcome has a formal definition. The adverse-event definition does not require a causal link to treatment, so the counts describe events occurring in the safety population rather than confirmed treatment-caused harms. The registry does not report blinded outcome adjudication or other procedures that might limit assessment differences.

Why does follow-up time matter?

Participants were observed for progressive disease and survival in 6-month intervals. Safety assessment is described from screening until 42 days after the last tecemotide dose, with assessment up to 3.6 years. In general, a participant followed longer has more opportunity for an event to be detected than someone followed for less time. Event rates that account for person-time can address unequal observation time, but the registry does not provide participant-level time at risk or such rates. A simple count cannot distinguish these exposure differences.

Time-to-event analyses also require information about when each participant experienced an event or was last known to be event-free. Such methods can account for incomplete follow-up under specified assumptions. The record lists overall survival as a secondary outcome but does not report survival estimates, event counts, censoring information, or an analysis method. It is not possible to infer what time-to-event approach was used.

What does uncertainty mean for these figures?

Every observed count is subject to sampling variability: a different set of participants could have produced different counts. In general, confidence intervals express a range of values compatible with data under a statistical model and assumptions. They help distinguish a precise estimate from one with substantial uncertainty. Confidence intervals for the posted safety counts or corresponding proportions are not reported in the registry record. A zero observed count in a group is not evidence that the event cannot occur; uncertainty remains, particularly when the group is limited in size.

Over-dispersion is a general concern when variation in event counts exceeds what a chosen statistical model expects. It can arise when people have differing underlying risks or exposure times. For participant-level binary outcomes, different follow-up and clinical characteristics can also make a simple common-risk model inadequate. The record does not report a model-based analysis of adverse-event counts, so it is not possible to say whether over-dispersion was assessed or relevant to any sponsor analysis.

What does the registry report about the analysis plan?

The posted record identifies the endpoint and analysis population, and it lists outcomes and adverse-event counts. It does not report a statistical analysis plan, a sample-size justification, an interim-analysis plan, or model specifications. No p-values or adjusted estimates are listed. The absence of these details means that readers cannot determine from the registry record whether additional analyses were prespecified or how any unposted analyses handled confounding, follow-up, or uncertainty.

Planning sample sizes derived from an observed effect are not observed trial results and are not a measure of the study’s achieved power. The registry does not report a sample-size justification for this follow-up study. Any planning illustration should be understood only as a hypothetical calculation under its stated assumptions, not as evidence that the trial was designed to detect a particular effect or had adequate power for a particular comparison.

10. Multiplicity, Missing Data and Analysis Populations

The record lists a primary safety outcome with several related categories: adverse events, serious adverse events, events leading to discontinuation, and events leading to death. Overall survival is listed as a secondary outcome. Considering multiple outcomes can increase the chance of finding at least one apparently notable result when formal statistical tests are performed. In general, multiplicity procedures can control that risk, but no testing hierarchy, adjustment, or multiplicity plan is reported in the registry record. No p-values are reported, so the posted figures do not permit an assessment of how multiple testing was handled.

Missing-data handling is also not reported in the registry record. The available entry does not describe how participants with incomplete safety follow-up were handled, whether event status was known through the end of follow-up for everyone, or how missing assessments were treated. These details matter because a participant without complete observation may have fewer opportunities for an event to be recorded. The record gives a safety timeframe but not participant-specific follow-up or a missingness summary.

The safety analysis population is defined as participants treated with tecemotide. This is narrower than the overall enrolled population of 27. The record does not provide a complete participant flow explaining entry into the safety set or the relationship between enrollment and the condition-specific at-risk counts. It also does not report separate analysis populations for overall survival or other outcomes.

The rationale for sample size, any interim analyses, and the statistical analysis plan are not reported in the registry record. It is therefore not possible to establish from this record how the investigators planned to address precision, multiplicity, incomplete observation, or analysis-population choices.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (16.7%), basal cell carcinoma (16.7%), bronchopneumonia (8.3%), sepsis (8.3%), staphylococcal infection (8.3%).

For non-small cell lung cancer, the registry lists 12 participants at risk for serious adverse events and 8 affected. For multiple myeloma, it lists 8 at risk and 0 affected. Other adverse-event entries list 12 at risk and 12 affected for non-small cell lung cancer, and 8 at risk and 7 affected for multiple myeloma. These are counts within the tecemotide-treated safety population, not comparisons with a randomized control group.

The serious adverse-event terms listed include Pneumonia and Basal cell carcinoma at 16.7% each; Bronchopneumonia, Sepsis, Staphylococcal infection, and Urosepsis are each listed at 8.3%. The denominator and method used for these term percentages are not reported in the registry record. The record defines serious events by specified outcomes, while the general adverse-event definition does not require a causal relationship to tecemotide. The term listings therefore do not establish that treatment caused the events.

Counts do not show event timing, duration, recurrence, or differences in participants’ follow-up exposure. The deaths field is not reported in the registry record. Results for adverse events leading to discontinuation or death are also not reported in the registry record.

12. What the Result Does, and Does Not, Mean

The reported figures describe adverse events recorded among participants treated with tecemotide in a follow-up study. The registry lists serious adverse-event counts by condition and gives counts for other adverse events. It also identifies serious adverse-event terms and their reported percentages. These observations are useful as a description of what was recorded in this study population and during the stated safety follow-up.

They do not establish that tecemotide caused any particular event. The event definition expressly includes occurrences without regard to a possible causal relationship. Nor do the figures establish that the treatment is safe or unsafe in a broader population. The study is a follow-up of people from earlier trials, includes limited condition-specific groups, and does not provide uncertainty intervals or detailed participant follow-up.

The record does not support a causal comparison with no intervention. Treatment was not randomized, and the observation group consisted of people with different prior treatment circumstances. Any difference between these groups could reflect baseline differences, prior treatment, treatment continuation decisions, or follow-up rather than an effect of tecemotide itself. The posted figures are not a like-for-like control comparison.

Overall survival is listed as a secondary outcome, but results are not reported in the registry record. The primary outcome description includes adverse events leading to discontinuation and adverse events leading to death, but corresponding results are not reported in the registry record. The registry also does not state why the trial was terminated. These gaps mean that the available information cannot answer questions about survival benefit, comparative effectiveness, or the reason for study termination.

In short, the figures describe recorded safety experience in this follow-up setting. They do not provide a randomized treatment effect, a complete account of outcome uncertainty, or evidence that an observed event was caused by treatment. Interpretation should stay within that descriptive scope.

13. Why This Trial Matters Statistically

This trial illustrates an important distinction between follow-up data and comparative evidence. A follow-up study can document events after people take part in earlier trials and can maintain observation of participants over time. Such information can be useful for describing safety experience and continued observation. However, when treatment continuation is not randomized, the resulting groups are not equivalent by design. Their counts should not be interpreted as if one group were a randomized control for the other.

It also highlights how outcome definition and analysis population shape interpretation. The primary endpoint counts participants with broad adverse-event categories, while the safety population includes only those treated with tecemotide. A count is directly readable, but its interpretation depends on who was included, how long they were observed, and what event definition was used. The registry gives a safety timeframe and a definition, yet does not provide participant-level follow-up or confidence intervals.

The record makes clear that a posted outcome label is not the same as a complete statistical result. Overall survival is listed as a secondary outcome, but no result is reported. Similarly, the primary endpoint description names events leading to discontinuation and death, but the corresponding result counts are not reported in the registry record. Recognizing the difference between listed outcomes and reported estimates is central to transparent evidence appraisal.

Finally, the study underscores why uncertainty and analysis plans matter. Small descriptive groups can yield uncertain estimates, and no confidence intervals or analysis plan are reported. The result is best treated as a record of observed adverse-event counts in a specific follow-up context, rather than as a test of efficacy or a definitive comparison of treatment strategies.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to the design and record. The study was open-label and nonrandomized, and the observation circumstances depended on prior treatment in feeder trials or discontinuation. This creates potential selection differences between participants who continued tecemotide and those who were observed without receiving it. The registry itself cautions that the arms are not a like-for-like control comparison.

The population was drawn from people who had participated in earlier sponsored tecemotide studies, so the record does not describe a newly recruited, broadly representative group. The listed conditions are non-small cell lung cancer and multiple myeloma. Overall enrollment was 27, while the safety analysis included only tecemotide-treated participants. The registry does not explain the relationship between overall enrollment and the group-specific at-risk counts.

Follow-up duration may differ among participants. The record describes safety assessment up to 3.6 years and observation for progressive disease and survival in 6-month intervals, but does not report participant-level exposure time, loss to follow-up, or completeness of event ascertainment. Counts therefore do not account for possible differences in time at risk.

The registry does not report confidence intervals, comparative estimates, survival results, or results for adverse events leading to discontinuation and death. The denominator and derivation of listed serious-event term percentages are not reported. Missing-data methods, sample-size justification, interim analyses, statistical analysis plan, and reason for termination are also not reported in the registry record. These omissions limit assessment of precision, completeness, and prespecification.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Common Safety Follow-up Trial of Tecemotide (L-BLP25) — NCT01423760.
• Registry record last updated 2016-10-06; status last verified 2016-08.
• Results first posted 2016-10-06.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01423760 is a terminated, open-label, nonrandomized follow-up trial of tecemotide (L-BLP25), with enrollment of 27 and conditions listed as non-small cell lung cancer and multiple myeloma. Participants transferring from earlier trials either continued tecemotide with safety assessments or were observed without treatment in this follow-up, depending on prior treatment history. Progressive disease and survival observation was scheduled in 6-month intervals.

The primary outcome counts participants with adverse events, serious adverse events, events leading to discontinuation, and events leading to death. The safety analysis included only tecemotide-treated participants. Condition-specific serious and other adverse-event counts and selected serious-event terms are reported. Overall survival is listed as a secondary outcome, but its results are not reported in the registry record.

The nonrandomized design does not provide a like-for-like control comparison. The registry record does not report the statistical analysis plan, missing-data methods, sample-size rationale, or reason for termination.